ViroMed Launches Joint Study With Biologics Delivery Systems
Posted on: Friday, 4 April 2008, 12:00 CDT
ViroMed has launched a joint study with Biologics Delivery Systems Group of Cordis, a Johnson & Johnson company.
The study will evaluate the efficacy of VM202 for the treatment of coronary artery disease, using Biologics Delivery Systems Group's Noga Cardiac Navigation System and the Myostar injection Catheter.
Successful completion of this study will facilitate the initiation of the US Phase I study, in which VM202, an angiogenic therapeutic product of ViroMed, will be delivered with the Noga injection system to patient with heart disease without the need for surgical intervention. Approval for this clinical trial in the US is expected during fourth quarter of 2008. Independently, the Phase I clinical trial for VM202 for the treatment of peripheral artery disease is ongoing at Minneapolis Heart Institute in the US.
Sunyoung Kim, CEO of ViroMed, said: "We hope and anticipate that this initial collaboration will lead to a fruitful and productive partnership between the two companies and will allow us to become a global player in the cardiovascular therapeutic market."
Source: Datamonitor
Related Articles
- K-State's Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year
- Method Created to Study Diseased Cells
- Atlantis Taking Microbes to Space to Study Disease
- Researchers to Study Cells at New Center
- AIDS Research Pioneer Speaks at WVU: Curran Has Studied Disease Since It Was First Discovered
- Study: Disease Afflicts Deer Flesh, Brain
- Study: Disease Will Kill 400M By 2015
- South Korea Takes Lead in Stem Cell Research
- Scientists Create Mice With Human Immune Systems
- Satellites Join Search for Source of Ebola Virus
 |
 |
User Comments (0)
RSS Feeds